True North Advisors, LLC Biomarin Pharmaceutical Inc Transaction History

True North Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$86.68 - $100.3 $251,372 - $290,870	-2,900 Reduced 33.33%	5,800 $502,000
Q2 2021 Jun 07, 2022	BUY	$75.51 - $84.79 $241,632 - $271,328	3,200 Added 58.18%	8,700 $725,000
Q4 2020 May 20, 2022	BUY	$72.61 - $90.2 $190,165 - $236,233	2,619 Added 90.91%	5,500 $482,000
Q3 2020 May 20, 2022	BUY	$71.87 - $131.03 $207,057 - $377,497	2,881 New	2,881 $219,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.5B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of True North Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on True North Advisors, LLC with notifications on news.